This is the second submission of this Conte Center for the Neuroscience of Mental Disorders (CCNMD) entitled """"""""The Neurobiology of Dopamine in Schizophrenia. Schizophrenia might result from neurodevelopmental disruptions involving multiple cortico-subcortical and intracortical networks. While the precise mapping of these alterations remains unclear, multiple lines of evidence suggest that prefrontal cortex (PFC) is critically involved in the neurocircuitry underlying the pathophysiology of schizophrenia. Within these circuits, dysregulations of DA (DA) and glutamate (GLU) transmission have been strongly implicated. The unifying hypothesis of the Center is that schizophrenia is associated with an imbalance of DA (DA) systems, characterized by a persistent deficit in prefrontal cortical DA function (contributing to the cognitive impairment observed in these patients) and an intermittent excess of subcortical DA function (contributing to the emergence of psychotic states). This DA imbalance might stem from altered PFC connectivity involving GLU transmission and from a failure of PFC to appropriately modulate DA function. The overall goal of the Center is to combine clinical imaging with Positron Emission Tomography (PET) and epigenetic and transgenic animal models in mice and rhesus monkeys to test this hypothesis. A set of interrelated clinical and preclinical investigations are proposed to 1) better characterize the existence of such a DA imbalance in schizophrenia; 2) explore the underlying biological mechanisms that might account for such a DA phenotype; 3) understand the consequence of this imbalance for brain functions, clinical symptoms and treatment. Six highly integrated projects are proposed, including two clinical imaging projects in patients with schizophrenia (Projects by Abi-Dargham and Laruelle) four preclinical projects, performed in rhesus monkeys (Projects by Haber and Javitt) and mice (Projects by Kandel and Rayport). These projects will investigate this single hypothesis with state-of-the art methodologies. Six cores will provide shared resources and support for these projects (Administrative, Biostatistics and Data management, Clinical, Brain Imaging, Molecular and Cellular, and Neurochemistry Cores). Prominent investigators from three Institutions (Columbia University, University of Rochester and Nathan Kline Research Institute) will bring specific research skills and collaborate closely in this translational investigation. By integrating basic and clinical research in a unique way, this Center will provide a fundamental advance in understanding the neural substrates underlying schizophrenia, the developmental etiology of this phenotype, and the implications of these findings for the development of new treatment modalities.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Specialized Center (P50)
Project #
1P50MH066171-01A1
Application #
6816305
Study Section
Special Emphasis Panel (ZMH1-BRB-P (05))
Program Officer
Zalcman, Steven J
Project Start
2004-09-24
Project End
2009-06-30
Budget Start
2004-09-24
Budget End
2005-06-30
Support Year
1
Fiscal Year
2004
Total Cost
$2,418,854
Indirect Cost
Name
New York State Psychiatric Institute
Department
Type
DUNS #
167204994
City
New York
State
NY
Country
United States
Zip Code
10032
Slifstein, Mark; van de Giessen, Elsmarieke; Van Snellenberg, Jared et al. (2015) Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. JAMA Psychiatry 72:316-24
Chuhma, Nao; Mingote, Susana; Moore, Holly et al. (2014) Dopamine neurons control striatal cholinergic neurons via regionally heterogeneous dopamine and glutamate signaling. Neuron 81:901-12
Poels, E M P; Kegeles, L S; Kantrowitz, J T et al. (2014) Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Mol Psychiatry 19:20-9
Poels, Eline M P; Kegeles, Lawrence S; Kantrowitz, Joshua T et al. (2014) Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings. Schizophr Res 152:325-32
Poels, Eline M P; Girgis, Ragy R; Thompson, Judy L et al. (2013) In vivo binding of the dopamine-1 receptor PET tracers [¹¹C]NNC112 and [¹¹C]SCH23390: a comparison study in individuals with schizophrenia. Psychopharmacology (Berl) 228:167-74
Kisby, Glen E; Moore, Holly; Spencer, Peter S (2013) Animal models of brain maldevelopment induced by cycad plant genotoxins. Birth Defects Res C Embryo Today 99:247-55
Mihali, Andra; Subramani, Shreya; Kaunitz, Genevieve et al. (2012) Modeling resilience to schizophrenia in genetically modified mice: a novel approach to drug discovery. Expert Rev Neurother 12:785-99
Ward, Ryan D; Simpson, Eleanor H; Richards, Vanessa L et al. (2012) Dissociation of hedonic reaction to reward and incentive motivation in an animal model of the negative symptoms of schizophrenia. Neuropsychopharmacology 37:1699-707
Abi-Dargham, Anissa; Xu, Xiaoyan; Thompson, Judy L et al. (2012) Increased prefrontal cortical D? receptors in drug naive patients with schizophrenia: a PET study with [¹¹C]NNC112. J Psychopharmacol 26:794-805
Li, Yan-Chun; Kellendonk, Christoph; Simpson, Eleanor H et al. (2011) D2 receptor overexpression in the striatum leads to a deficit in inhibitory transmission and dopamine sensitivity in mouse prefrontal cortex. Proc Natl Acad Sci U S A 108:12107-12

Showing the most recent 10 out of 31 publications